CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed to showcase latest clinical progress on neflamapimod at Canaccord Genuity Growth Conference

CervoMed Inc., a clinical-stage biotech company focused on treatments for age-related brain disorders, announced management's participation in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. They will discuss recent advancements in the clinical development of neflamapimod, their lead drug targeting neuroinflammation and neurodegeneration. Key updates include FDA alignment on a potential registration path for neflamapimod in dementia with Lewy bodies (DLB), ongoing Phase 2a trials in frontotemporal disorders, and plans to initiate a Phase 3 DLB trial pending partnership or financing.

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CRVO

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

Neflamapimod targets neuroinflammation and neurodegeneration to treat age-related brain disorders, including DLB and frontotemporal disorders.
FDA has aligned with CervoMed on a potential registration path for neflamapimod in DLB, marking regulatory progress.
Ongoing and upcoming clinical trials, including Phase 2a for nfvPPA and EXPERTS-ALS Phase 2a trial, indicate continued pipeline development.
The biotech and pharmaceutical sectors are directly impacted, as well as healthcare investors focusing on neurodegenerative disease treatments.

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026.

During the fireside chat, management will share recent progress in neflamapimod's clinical development program.

Presentation Details
Format: Fireside Chat
Date: Tuesday, August 11, 2026
Time: 11:30 – 11:55 AM ET
Webcast Link: https://event.summitcast.com/view/WuFmFdTcA9mVsUGHZJFU62/guest_book?session_id=CbcwtmiHhUmzr5EAgGgHjJ

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Contacts

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902

Risks

Initiation of Phase 3 trial in DLB depends on securing a partnership or additional financing, introducing funding risk.
Clinical trial outcomes remain uncertain until completion and data analysis, posing clinical and regulatory risk.
Market acceptance and competition in neurodegenerative therapies could impact commercial success, adding market risk.

Menu

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

Key Points

Risks

More from Press Releases